BeiGene announced that the Center for Drug Evaluation, or CDE, of the China National Medical Products Administration, or NMPA, has accepted a supplemental biologics license application, or sBLA, for tislelizumab in patients with first-line unresectable or metastatic hepatocellular carcinoma, or HCC.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BGNE:
